{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:41:00Z","timestamp":1782549660101,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    O6-methylguanine-DNA methyltransferase (MGMT) has been linked with alkylating agent resistance and tumor growth suppression. However, its role remains undetermined in pancreatic neuroendocrine tumors (Pan-NET). The MGMT expression was examined by immunohistochemistry in 142 patients to evaluate MGMT immunoreactivity and clinicopathological factors. We analyzed the relationship between MGMT expression and treatment efficacy in 19 patients who received STZ-based regimens. In 142 Pan-NET, 97 cases (68.3%) were judged as MGMT-positive and 45 cases (31.6%) as negative. MGMT negativity was significantly more common in NET-G2 (62.5%) than in NET-G1 (11.2%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). MGMT-negative cases were associated significantly with larger tumor size (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01), higher Ki-67 index (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01), higher mitotic index (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), and more frequent liver metastasis (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Of the 19 cases treated with STZ, 6 cases were determined as SD and 4 cases as PD in MGMT-positive patients (N\u2009=\u200910), while 5 cases were determined as PR and 4 cases as SD in MGMT-negative patients (N\u2009=\u20099). Progression-free survival in MGMT-negative cases was significantly better than in MGMT-positive cases (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). MGMT expression was lower in NET-G2 than in NET-G1, and STZ-based regimens improved the therapeutic outcomes of MGMT-negative Pan-NET. These findings indicate that NET-G2 may represent a better therapeutic target for STZ treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-34666-y","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T08:02:00Z","timestamp":1683705720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens"],"prefix":"10.1038","volume":"13","author":[{"given":"Kohei","family":"Yagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kinowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"34666_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1677\/ERC-07-0221","volume":"15","author":"TR Halfdanarson","year":"2008","unstructured":"Halfdanarson, T. R., Rubin, J., Farnell, M. B., Grant, C. S. & Petersen, G. M. Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr. Relat. Cancer 15, 409\u2013427 (2008).","journal-title":"Endocr. Relat. Cancer"},{"key":"34666_CR2","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1002\/cncr.23883","volume":"113","author":"O Hauso","year":"2008","unstructured":"Hauso, O. et al. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer 113, 2655\u20132664 (2008).","journal-title":"Cancer"},{"key":"34666_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00535-009-0194-8","volume":"45","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J. Gastroenterol. 45, 234\u2013243 (2010).","journal-title":"J. Gastroenterol."},{"key":"34666_CR4","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao, J. C. et al. One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063\u20133072 (2008).","journal-title":"J. Clin. Oncol."},{"key":"34666_CR5","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1200\/JCO.2010.33.0688","volume":"29","author":"F Panzuto","year":"2011","unstructured":"Panzuto, F. et al. Metastatic and locally advanced pancreatic endocrine carcinomas: Analysis of factors associated with disease progression. J. Clin. Oncol. 29, 2372\u20132377 (2011).","journal-title":"J. Clin. Oncol."},{"key":"34666_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel, M. et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103, 172\u2013185 (2016).","journal-title":"Neuroendocrinology"},{"key":"34666_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00280-018-3656-y","volume":"82","author":"H Shibuya","year":"2018","unstructured":"Shibuya, H. et al. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: Focus on weekly regimens and monotherapy. Cancer Chemother. Pharmacol. 82, 661\u2013668 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"34666_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00432-019-03109-5","volume":"146","author":"H Ono","year":"2020","unstructured":"Ono, H. et al. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms. J. Cancer Res. Clin. Oncol. 146, 793\u2013799 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"34666_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/1078-0432.CCR-05-2543","volume":"12","author":"L Liu","year":"2006","unstructured":"Liu, L. & Gerson, S. L. Targeted modulation of MGMT: Clinical implications. Clin. Cancer Res. 12, 328\u2013331 (2006).","journal-title":"Clin. Cancer Res."},{"key":"34666_CR10","first-page":"793","volume":"59","author":"M Esteller","year":"1999","unstructured":"Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B. & Herman, J. G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793\u2013797 (1999).","journal-title":"Cancer Res."},{"key":"34666_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"34666_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459\u2013466 (2009).","journal-title":"Lancet Oncol."},{"key":"34666_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707\u2013715 (2012).","journal-title":"Lancet Oncol."},{"key":"34666_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstrom","year":"2012","unstructured":"Malmstrom, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916\u2013926 (2012).","journal-title":"Lancet Oncol."},{"key":"34666_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00432-012-1312-1","volume":"138","author":"S Mason","year":"2012","unstructured":"Mason, S. & McDonald, K. MGMT testing for glioma in clinical laboratories: Discordance with methylation analyses prevents the implementation of routine immunohistochemistry. J. Cancer Res. Clin. Oncol. 138, 1789\u20131797 (2012).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"34666_CR16","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","volume":"13","author":"S Ekeblad","year":"2007","unstructured":"Ekeblad, S. et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 13, 2986\u20132991 (2007).","journal-title":"Clin. Cancer Res."},{"key":"34666_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","volume":"15","author":"MH Kulke","year":"2009","unstructured":"Kulke, M. H. et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 15, 338\u2013345 (2009).","journal-title":"Clin. Cancer Res."},{"key":"34666_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000365514","volume":"100","author":"AM Schmitt","year":"2014","unstructured":"Schmitt, A. M. et al. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms. Neuroendocrinology 100, 35\u201344 (2014).","journal-title":"Neuroendocrinology"},{"key":"34666_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bjc.2014.660","volume":"112","author":"T Walter","year":"2015","unstructured":"Walter, T. et al. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: Prognostic relevance and association with response to alkylating agents. Br. J. Cancer 112, 523\u2013531 (2015).","journal-title":"Br. J. Cancer"},{"key":"34666_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1530\/ERC-16-0147","volume":"23","author":"M Cives","year":"2016","unstructured":"Cives, M. et al. Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 23, 759\u2013767 (2016).","journal-title":"Endocr. Relat. Cancer"},{"key":"34666_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/ERC-16-0117","volume":"23","author":"J Cros","year":"2016","unstructured":"Cros, J. et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 23, 625\u2013633 (2016).","journal-title":"Endocr. Relat. Cancer"},{"key":"34666_CR22","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/MEG.0000000000000874","volume":"29","author":"P Girot","year":"2017","unstructured":"Girot, P. et al. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. Eur. J. Gastroenterol. Hepatol. 29, 826\u2013830 (2017).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"34666_CR23","doi-asserted-by":"publisher","first-page":"104046","DOI":"10.18632\/oncotarget.22001","volume":"8","author":"DH Owen","year":"2017","unstructured":"Owen, D. H. et al. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget 8, 104046\u2013104056 (2017).","journal-title":"Oncotarget"},{"key":"34666_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12020-017-1474-3","volume":"60","author":"D Campana","year":"2018","unstructured":"Campana, D. et al. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: An observational retrospective multicenter study. Endocrine 60, 490\u2013498 (2018).","journal-title":"Endocrine"},{"key":"34666_CR25","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.21873\/anticanres.11590","volume":"37","author":"S Krug","year":"2017","unstructured":"Krug, S. et al. Impact of therapy sequence with alkylating agents and MGMT status in patients with advanced neuroendocrine tumors. Anticancer Res. 37, 2491\u20132500 (2017).","journal-title":"Anticancer Res."},{"key":"34666_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-018-3700-y","volume":"83","author":"S Hijioka","year":"2019","unstructured":"Hijioka, S. et al. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemother. Pharmacol. 83, 43\u201352 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"34666_CR27","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling, A. et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15, e8-21 (2014).","journal-title":"Lancet Oncol"},{"key":"34666_CR28","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3, 1335\u20131342 (2017).","journal-title":"JAMA Oncol"},{"key":"34666_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1530\/ERC-21-0034","volume":"28","author":"O De Rycke","year":"2021","unstructured":"De Rycke, O. et al. Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 28, 457\u2013466 (2021).","journal-title":"Endocr Relat Cancer"},{"key":"34666_CR30","doi-asserted-by":"publisher","first-page":"e27889","DOI":"10.1371\/journal.pone.0027889","volume":"6","author":"K Konishi","year":"2011","unstructured":"Konishi, K. et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS ONE 6, e27889 (2011).","journal-title":"PLoS ONE"},{"key":"34666_CR31","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1038\/sj.onc.1205600","volume":"21","author":"M Esteller","year":"2002","unstructured":"Esteller, M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 21, 5427\u20135440 (2002).","journal-title":"Oncogene"},{"key":"34666_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2407-13-79","volume":"13","author":"JC Santos","year":"2013","unstructured":"Santos, J. C., Bastos, A. U., Cerutti, J. M. & Ribeiro, M. L. Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma. BMC Cancer 13, 79 (2013).","journal-title":"BMC Cancer"},{"key":"34666_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","volume":"10","author":"KJ Dedes","year":"2011","unstructured":"Dedes, K. J. et al. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 10, 1192\u20131199 (2011).","journal-title":"Cell Cycle"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34666-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34666-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34666-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T08:05:26Z","timestamp":1683705926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34666-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34666"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34666-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2161835\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-2161835\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7535"}}